Evidence map›Paper›PMID 20016043›Full record

ArticleClinical and vaccine immunology : CVI2010

Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.

Jieh-Juen Yu, Tatareddy Goluguri, M Neal Guentzel, James P Chambers, Ashlesh K Murthy, Karl E Klose, Thomas G Forsthuber, Bernard P Arulanandam

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Immunity to Francisella.Frontiers in microbiology · 2011
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jieh-Juen YuSouth Texas Center for Emerging Infectious Diseases, One UTSA Circle, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Tatareddy Goluguri
M Neal Guentzel
James P Chambers
Ashlesh K Murthy
Karl E Klose
Thomas G Forsthuber
Bernard P Arulanandam
Texas Center for Infectious Disease · US

Funding

Tularemia: Pathogenesis and Host ResponseP01AI057986 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI KLOSE, KARL E · 2005 to 2009
$6.1M
NIAID NIH HHS P01 AI057986
6 · The paper itself

Abstract

There is no licensed vaccine against the intracellular pathogen Francisella tularensis. The use of conventional mouse strains to screen protective vaccine antigens may be problematic, given the differences in the major histocompatibility complex (MHC) binding properties between murine and human antigen-presenting cells. We used engineered humanized mice that lack endogenous MHC class II alleles but that express a human HLA allele (HLA-DR4 transgenic [tg] mice) to identify potential subunit vaccine candidates. Specifically, we applied a biochemical and immunological screening approach with bioinformatics to select putative F. tularensis subsp. novicida T-cell-reactive antigens using humanized HLA-DR4 tg mice. Cell wall- and membrane-associated proteins were extracted with Triton X-114 detergent and were separated by fractionation with a Rotofor apparatus and whole-gel elution. A series of proteins were identified from fractions that stimulated antigen-specific gamma interferon (IFN-gamma) production, and these were further downselected by the use of bioinformatics and HLA-DR4 binding algorithms. We further examined the validity of this combinatorial approach with one of the identified proteins, a 19-kDa Francisella tularensis outer membrane protein (designated Francisella outer membrane protein B [FopB]; FTN_0119). FopB was shown to be a T-cell antigen by a specific IFN-gamma recall assay with purified CD4(+) T cells from F. tularensis subsp. novicida DeltaiglC-primed HLA-DR4 tg mice and cells of a human B-cell line expressing HLA-DR4 (DRB1*0401) functioning as antigen-presenting cells. Intranasal immunization of HLA-DR4 tg mice with the single antigen FopB conferred significant protection against lethal pulmonary challenge with an F. tularensis subsp. holarctica live vaccine strain. These results demonstrate the value of combining functional biochemical and immunological screening with humanized HLA-DR4 tg mice to map HLA-DR4-restricted Francisella CD4(+) T-cell epitopes.

Indexed as

Administration, IntranasalAnimalsAntigens, BacterialBacterial ProteinsCells, CulturedComputational BiologyFrancisella tularensisHLA-DR4 AntigenHumansInterferon-gammaMiceMice, SCIDMice, TransgenicSurvival AnalysisT-LymphocytesTularemiaAntigens, BacterialBacterial ProteinsHLA-DR4 AntigenInterferon-gamma

Identifiers

PMID20016043
PMCPMC2815527
OpenAlexW2163515488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.